David Siner

David Siner has extensive work experience in the pharmaceutical industry, with a focus on CMC (Chemistry, Manufacturing, and Controls). David currently holds the position of Head CMC & Drug Development at PQE Group since January 2020. Prior to this, they served as the Chief Development Officer CMC at Vallon Pharmaceuticals from December 2017 to December 2019. In this role, they were responsible for leading the CMC department and developing abuse deterrence formulations of CNS related products.

Before joining Vallon Pharmaceuticals, David worked as a Senior Director CMC at Alcobra Pharma from August 2014 to December 2017. Prior to that, they served as the Director CMC at Neurim from July 2007 to July 2014. Additionally, David has experience as a Chemist at Charles River Laboratories from 2004 to 2007 and as a Scientist at Mirador DNA Design from 2003 to 2005.

David Siner's education history includes a Bachelor's degree in Chemistry from Technion - Israel Institute of Technology. David also holds a Master's degree in Developmental Biology and Embryology from Tel Aviv University.